miércoles, 25 de junio de 2025

Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options The company hopes its non-small cell lung cancer drug will be used where predecessors have not

https://www.statnews.com/2025/06/24/nuvalent-lung-cancer-ros1-zidesamtinib/

No hay comentarios:

Publicar un comentario